Skip to main content
Clinical Trials/NCT05811689
NCT05811689
Completed
Not Applicable

Trabecular Bone Score (TBS) as an Innovative Parameter Evaluation for Bone Disease's in Multiple Sclerosis (MS) Patients and Impact of Osteoporosis on the Quality of Life of Patients With MS

IRCCS Centro Neurolesi "Bonino-Pulejo"1 site in 1 country300 target enrollmentFebruary 14, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
IRCCS Centro Neurolesi "Bonino-Pulejo"
Enrollment
300
Locations
1
Primary Endpoint
DXA scanner (Horizon© DXA System)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Assess bone quality in MS patients through TBS and evaluate the potential effects exerted by different drugs used in MS treatment, which may affect BMD and TBS in MS patients

Registry
clinicaltrials.gov
Start Date
February 14, 2021
End Date
February 15, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • diagnosis of MS according to the latest revision of McDonald's criteria;
  • patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (SPMS);
  • absence of cortisone therapy for at least 6 months;

Exclusion Criteria

  • patients already being treated with anti-osteoporotic drugs;
  • medical conditions that preclude the execution of the densitometric examination

Outcomes

Primary Outcomes

DXA scanner (Horizon© DXA System)

Time Frame: 6 months

The DXA scanner (Horizon© DXA System) measures bone mineral content relative to bone area.

Secondary Outcomes

  • Bone Mineral Density(6 months)

Study Sites (1)

Loading locations...

Similar Trials